### ORIGINAL ARTICLE



## Prospective multicenter registration study of colorectal cancer: significant variations in radicality and oncosurgical quality—Swiss Group for Clinical Cancer Research Protocol SAKK 40/00

Christoph A. Maurer<sup>1,2</sup> · Daniel Dietrich<sup>3</sup> · Martin K. Schilling<sup>4</sup> · Urs Metzger<sup>5</sup> · Urban Laffer<sup>6</sup> · Peter Buchmann<sup>7</sup> · Bruno Lerf<sup>8</sup> · Peter Villiger<sup>9</sup> · Gian Melcher<sup>10</sup> · Christian Klaiber<sup>11</sup> · Christian Bilat<sup>12</sup> · Peter Brauchli<sup>3</sup> · Luigi Terracciano<sup>13</sup> · Katharina Kessler<sup>1</sup>

Accepted: 21 September 2016 / Published online: 7 October 2016 © Springer-Verlag Berlin Heidelberg 2016

#### Abstract

*Purpose* This study aimed to investigate in a multicenter cohort study the radicality of colorectal cancer resections, to assess the oncosurgical quality of colorectal specimens, and to compare the performance between centers.

*Methods* One German and nine Swiss hospitals agreed to prospectively register all patients with primary colorectal cancer resected between September 2001 and June 2005. The median number of eligible patients with one primary tumor included per center was 95 (range 12–204).

*Results* The following variations of median values or percentages between centers were found: length of bowel specimen 20– 39 cm (25.8 cm), maximum height of mesocolon 6.5–12.5 cm (9.0 cm), number of examined lymph nodes 9–24 (16), distance

Parts of the study results have been presented at the annual congress of the Swiss Surgical Society in Lugano, Switzerland, June 2006, at the 7. BIC Biebrich International Conference on Colorectal Cancer in Wiesbaden, Germany, October 2010, and at the annual congress of the Swiss Surgical Society in Bern, Switzerland, May 2015.

Christian Klaiber is deceased October 2013

Christoph A. Maurer christoph.maurer@hin.ch

- <sup>1</sup> Departments of Surgery of Hospital of Liestal, Liestal, Switzerland
- <sup>2</sup> Hirslanden Group, Clinic Beau-Site, Schänzlihalde 11, 3000 Bern, Switzerland
- <sup>3</sup> Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
- <sup>4</sup> University Hospital of Homburg/Saar (DE), Homburg, Germany
- <sup>5</sup> Triemli Hospital of Zürich, Zürich, Switzerland

to nearer bowel resection margin in colon cancer 4.8–12 cm (7 cm), and in rectal cancer 2–3 cm (2.5 cm), central ligation of major artery 40–97 % (71 %), blood loss 200–500 ml (300 ml), need for perioperative blood transfusion 5–40 % (19 %), tumor opened during mobilization 0–11 % (5 %), T4-tumors not en-bloc resected 0–33 % (4 %), inadvertent perforation of mesocolon/mesorectum 0–8 % (4 %), no-touch isolation technique 36–86 % (67 %), abdominoperineal resection for rectal cancer 0–30 % (17 %), rectal cancer specimen with circumferential margin  $\leq$ 1 mm 0–19 % (10 %), in-hospital mortality 0–6 % (2 %), anastomotic leak or intra-abdominal abscess 0–17 % (7 %), re-operation 0–17 % (8 %).

*Conclusion* In colorectal cancer, surgery considerable variations between different centers were found with regard to radicality

- <sup>6</sup> Hospital of Biel, Biel, Switzerland
- <sup>7</sup> Waid Hospital of Zürich, Zürich, Switzerland
- <sup>8</sup> Hospital of Zug, Zug, Switzerland
- 9 Hospital of of Chur, Chur, Switzerland
- <sup>10</sup> Hospital of of Uster, Uster, Switzerland
- <sup>11</sup> Hospital of of Aarberg, Aarberg, Switzerland
- <sup>12</sup> Hospital of Ilanz, Ilanz, Switzerland
- <sup>13</sup> Institute of Pathology, University of Basel, Basel, Switzerland

and oncosurgical quality, suggesting a potential for targeted improvement of surgical technique.

**Keywords** Colorectal · Cancer · Surgery · Pathology · Radicality · Quality

#### Introduction

Short-term and long-term outcomes of patients with colorectal cancer (CRC) are strongly influenced by the quality of surgery. Many studies in this field including one of our group [1] have shown that the variability of performance among surgeons relates to the surgeon's special interest [2, 3], the surgeon's education and the annual case load [1, 3–9]. Hence, surgeons seem to be an important prognostic factor for their patients [6]. However, how an excellent or good CRC surgeon differs from an average or even a poorly performing one is only barely understood [10]. And since critical self-assessments among surgeons are rarely published, it seems difficult to obtain precise information with regard to the quality of their CRC surgery.

From the literature, only little evidence with regard to necessary surgical radicality or oncosurgical quality is available for cancer of the rectum, and even less for the colon [10–15]. Many issues of surgical technique such as the impact of total mesorectal excision, of blood loss, of short versus long segment colonic resection, of abdominoperineal versus sphincter preserving resection, of high versus intermediate or even low arterial tie, of inadvertent tumor opening will hardly ever be investigated in randomized controlled trials due to ethical and consent reasons. For many of the open scientific questions in CRC surgery, large prospective cohort studies remain an adequate tool for investigation. Adjuvant and neoadjuvant trials for CRC are in urgent need of standardization of surgery and of pathological work-up to reliably compare the specific anticancerous effect of different therapies.

The aim of the present multicenter cohort study in CRC patients was to assess meticulously and prospectively the surgical radicality and the oncosurgical quality of procedures and specimens, for the whole study population as well as for each participating center separately. Furthermore, we intended to identify the most important rules for obtaining long-term success in the future. As a consequence, this study might also create an instrument for quality control and for special education in this field of surgery.

#### Methods

Nine surgical departments from Switzerland and one from Germany agreed to prospectively register patients with resection of primary CRC within a central database of the Swiss Group for Clinical Cancer Research (SAKK) in Bern. The following categories of surgical institutions participated: one university hospital, five hospitals affiliated with a university, two district hospitals, and two small regional hospitals. The surgical units of all the participating hospitals had a special interest and special expertise in CRC surgery. A data manager of the SAKK periodically visited the participating hospitals to check that all consecutive patients had been registered, especially the emergency cases as well as the complicated cases. The study was approved by the scientific committee of the SAKK as well as by all responsible local ethics committees.

Between September 2001 and June 2005, 1502 patients with surgery for primary CRC were registered (initials, date of birth, and center, only). Informed consent was requested before surgery. Four hundred and sixty-two patients did not consent and hence no further data were collected and analyzed. In addition, thirthy-six patients were excluded from the analysis because the primary tumor was not resected (n = 8) or because the final diagnosis was not primary adenocarcinoma of the colorectum (n = 28). Patients with histologically proven rectal cancer and complete remission after combined neoadjuvant radiochemotherapy, and patients without any cancerous tissue left in the colorectal specimen following endoscopic removal of a malignant colorectal polyp were not excluded from the analysis. In total, the study population consists of 1004 patients, 965 patients with one resected and histologically proven primary adenocarcinoma of the colorectum forming the base of the present study, and 39 patients with two or more synchronous primary colorectal carcinomas which were analyzed separately.

The following underlying or concomitant colorectal diseases were recorded: six patients with ulcerative colitis, one patient with Crohn's disease, but no patient with familial adenomatous polyposis.

#### Special features of the standardized surgery form

To minimize discrepancies in nomenclature of the types of resection and of major arteries as well as to standardize reporting, the precise tumor location, the extent of bowel resection, and the ligature sites of major arterial blood supply had to be marked in a given figure of the colorectum including the arterial blood vessels (Fig. 1). The rectum was graduated in 1-cm steps.

#### Special features of the standardized pathology form

The pathologists had to declare the measuring conditions for each specimen, whether the measurement of the specimen was done in a native or in a formaline-fixed state and whether it was done under tension or not. For lymph node examination, no fat clearance method was used in any of the participating institutes of pathology. Furthermore, the maximum height of




Fig. 1 Extract from the standardized surgery form: surgeons precisely had to mark tumor site, margins of bowel resection and site(s) of arterial ligation for each resection of colorectal cancer

the specimen's mesocolon had to be assessed, i.e., measurement of the distance from the most central arterial ligature perpendicularly to the bowel wall. The pathology form demanded a statement with regard to the presence of lymphatic, venous, and perineural invasion.

#### Special features of the standardized complication form

Within 2 weeks of discharge from the hospital, a completed standardized complication form including need of perioperative blood transfusion, re-operation, and in-hospital death had to be sent to the SAKK coordinating center for each patient.

# Patients with multiple synchronous primary colorectal carcinomas

Thirty-nine (3.9%) of 1004 patients had two or more synchronous primary CRCs. Even, there were 6 (0.6%) out of these 39 patients with more than 2 synchronous adenocarcinomas of the colorectum. For each cancer, the pathologists had to send a separate pathology form. Five out of 39 patients with more than one synchronous primary CRC had two separate colorectal segments resected. For each resected and tumor-bearing segment of the colorectum, the surgeons had to send a separate surgery form. The primary with the highest tumor stage was relevant for further analyses [16].

#### **Registration of data**

The data from all forms was entered in a central database of the SAKK Coordinating Center in Bern by an independent data manager with medical education. According to a key provided by the study chair, tumor locations, dissection sites of the bowel, and ligature sites of major arteries were then decoded from the figure of the surgery form (Fig. 1) by co-workers of the SAKK Coordinating Center and added to the database.

Furthermore, from all patients, copies of the surgical report and the pathology were stored in the SAKK Coordinating Center and used to clarify any potential discrepancies. All patient data was checked by at least two independent *people*, i.e., by a staff surgeon of the first author's surgical department (K.K.) and by a co-worker of the SAKK. The final review was done by the chairman of the study (C.A.M.) and the statisticians of the SAKK.

#### Definitions

The site of rectum was defined as 0-15 cm from anal verge. The site of rectosigmoid junction was defined as colonic section between >15 and 20 cm from anal verge. For determination of the tumor site, the lower border of the tumor was decisive, e.g., a carcinoma from 14 to 17 cm from anal verge was assigned to rectal cancer. The following ligature sites of major arteries, with respect to removal of the corresponding lymph node levels, have been discriminated: central, intermediate, peripheral.

#### Statistical methods

Exploratory analysis of prospective data was performed for the short-term outcome of this study. Summary statistics of all variables defining patient and tumor characteristics as well as the assessment of surgical radicality and oncosurgical quality are presented as median and range, or as a frequency and proportion. To compare the results across centers, Kruskal-Wallis rank sum test was applied to quantitative variables and chi-square test to qualitative/categorical variables. Monte Carlo approximation was used for low frequencies. The reported *p* values are two-sided without correction for multiple testing.

Associations between variables were checked by Wilcoxon rank sum tests or chi-square tests for frequency tables or for logistic regression models. Low frequencies were compared by Fisher's exact test. Correlations were evaluated using the Spearman method.

#### Results

#### Results regarding patient and tumor characteristics

Characteristics of participating centers are presented in Table 1. Patient and tumor characteristics of the study population of N = 965 evaluable patients with a single primary tumor are summarized in Table 2. In the latter, each criterion

Table 1

#### Characteristics of participating surgical departments No. Variable Statistics Total Dept1 Dept2 Dept3 Dept4 Dept5 Dept6 Dept7 Dept8 Dept9 Dept 10 1 Case load per year per dept. See<sup>a</sup> 263.5 46.8 9.9 67.7 133.8 25.1 4.0 27.4 76.0 50.3 21.0 2 Number of senior surgeons Frequency 34 2 2 5 8 4 1 2 7 2 1 97 3 Evaluable patients with one primary CRC 92 12 163 13 99 178 45 Frequency 965 204 62 Evaluable patients with two or more 2 6 10 3 0 5 3 3 4 Frequency 39 6 1 primary CRC

Dept. surgical department, CRC colorectal cancer

<sup>a</sup> For calculation of the annual case load per center, total numbers of colorectal cancer resections including the excluded patients have been considered, as well as the different lengths of study participation

Table 2	Patient and tumor characteristics, analyzed as overall statistics and per each surgical department
---------	--

No.	Variable	Overall sample size	No. of centers	Statistics	Categories	Overall statistics	Range in statistics of centers	P value
1	Age (years)	965	10	Median		70	63–76	<.0001
2	Sex	965	10	Proportion	Female	0.39	0.34-0.51	0.3933
3	ASA score	965	10	Proportion	1 2	0.13 0.56	0.07–0.31 0.47–0.67	0.0005
					3	0.29	0.15-0.36	
					4–5	0.02	0-0.07	
4	Body mass index (kg/m <sup>2</sup> )	965	10	Median		25.4	24.1–26.4	0.0079
5	Patients with rectal cancer	965	10	Proportion		0.40	0-0.53	<.0001
6	Rectal cancers treated with neoadjuvant radiotherapy	384	9	Proportion		0.28	0.09–0.63	<.0001
7	pT-stage	964	10	Proportion	0 + is 1	0.02 0.09	0–0.06 0–0.16	0.0004
					2	0.18	0.08-0.42	
					3	0.58	0.53-0.65	
					4	0.13	0-0.23	
8	pN-stage	960	10	Proportion	0 1	0.58 0.21	0.51–0.67 0.08–0.29	0.7917
					2	0.21	0.15-0.25	
9	M-stage	964	10	Proportion	0 1	0.83 0.17	0.77–0.92 0.08–0.23	0.4386
10	UICC-stage	959	10	Proportion	0 I	0.02 0.22	0–0.05 0.11–0.42	0.0166
					II	0.31	0.22-0.43	
					III	0.28	0.23-0.32	
					IV	0.17	0.08-0.23	
11	Grading	930	10	Proportion	1–2 3–4	0.76 0.24	0.55–0.92 0.08–0.45	<.0001
12	Maximum diameter of primary (cm)	922	10	Median		4	3–4.5	<.0001
13	Specimens measured after formaline fixation	961	10	Proportion		0.90	0.77-1	<.0001
14	Patients operated by laparoscopy	965	10	Proportion		0.08	0-0.65	<.0001
15	Conversion to open operation	80	8	Proportion		0.13	0-0.50	0.5948
16	Emergency large bowel resection	965	10	Proportion		0.07	0-0.16	<.0001
17	Stoma formation in colon cancer patients	581	10	Proportion		0.05	0-0.09	0.1960
18	Stoma formation in rectal cancer patients	384	9	Proportion		0.69	0.35-0.80	0.0001
19	Distance of rectal cancers from anal verge (cm)	384	9	Median		7	6–11	0.0234

Dept. surgical department, ASA American Society of Anesthesiology, UICC International Union Against Cancer

is presented as a result of the whole study population and as the range of the 10 participating centers. A detailed Table 5 with results for each center can be found in the Appendix. Figure 2 shows the distribution pattern primary tumors of the study population.

#### Surgical radicality and oncosurgical quality

The results regarding surgical radicality and oncosurgical quality are depicted in Tables 3 and 4, again for the study population and as range of the 10 participating centers. Detailed results for each center are depicted in the Appendix, Tables 6 and 7.

With regard to the no-touch isolation technique according to Turnbull [17], i.e., venous ligature, arterial ligature, and closure of bowel lumen close to the tumor before tumor mobilization, the frequency of these single steps is depicted in Table 4, item 15. All three steps of this no-touch isolation technique were completed in 404 resections (41.9 %), two steps in 251 resections (26.0 %), one step in 73 (7.6 %) resections, and zero steps in 236 resections (24.5 %).

In 50 resections (5.2 %), the tumor was opened during tumor mobilization or colorectal dissection, in 31 resections (3.2 %) iatrogenically and in 19 resections (2.0 %) due to underlying spontaneous perforation. Multivisceral resections due to potentially tumorous infiltration of adherent neighboring organs were performed in 59 resections (6.1 %), 52 of these 59 as en-bloc resection (88.1 %).

Microscopically, proximal or distal bowel resection margins were infiltrated by tumor in 15 specimens, i.e., 1.6 % of all specimens, 3 are colon cancer specimens (0.5 % of colon cancer specimens), and 12 are rectal cancer specimens (3.1 % of rectal cancer specimens). In addition, cancer was found within 3 stapler doughnuts. Of the patients without locoregional R2-resection and without transanal local excision




Fig. 2 Distribution of tumor locations (965 patients)

(n = 930), 68 had either tumor infiltration of the bowel resection margin (n = 13), infiltration of the circumferential rectal resection margin (n = 25), spontaneous or iatrogenic tumor perforation (n = 38). Eight out of these 68 patients had a combination of such findings. This results in a R1-resection rate of 7.3 % (68/930), 2.9 % for colon cancer (16/557), and 13.9 % for rectal cancer (52/373).

Concomitant excision of liver metastases was done in 49 colorectal resections (5.1 %), in 24 of these 49 with a curative intent with no gross tumor left. Gross evidence of residual tumor was present following 145 colorectal resections (15.0 %), in 15 cases (1.5 %) locoregionally only, in 116 cases (11.8 %) at distant sites only and in 14 cases (1.5 %) both locoregionally and at distant sites, resulting in a locoregional R2resection rate of 3.0 % (29/965), 4.0 % for colon cancer (23/581), and 1.6 % for rectal cancer (6/384).

Regarding the measurement conditions, 862 out of 965 specimens (89.3 %) were measured after fixation in formaline, 58 (6.0 %) prior to formaline fixation and without stretching, and 35 (3.6 %) prior to formaline fixation but with stretching, i.e., under tension. No information about stretching or formaline fixation fixation or both was available in 10 (1.0 %) specimens.

Micrometastasis, defined as tumor deposits of up to 2 mm according to UICC [16], were detected as sole lymph node metastasis in an additional 14 (1.5 %) patients, 2 of them by immunohistochemistry only. *Serial* sections of lymph nodes were applied selectively in 130 (13.5 %) specimens.

A moderate correlation between the length of specimens and the number of examined lymph nodes was detected (Spearman correlation coefficient 0.34, p < 0.001). A weak correlation was found between the height of mesocolon and the number of examined lymph nodes (Spearman correlation coefficient 0.09, p = 0.033).

#### Mortality and surgical morbidity

The number of deaths during hospital stay was 24 (2.5 %), a median of 9.5 (1–61) days after surgery. Eighty-one patients (8.4 %) needed a re-operation after a median of 9 (0–121) days due to complications following primary surgery. The following frequencies of surgery-related complications were encountered: anastomotic leak and/or intra-abdominal abscess 64 (6.6 %), postoperative hemorrhage 21 (2.2 %), wound infection 97 (10.1 %), abdominal wall rupture 16 (1.7 %), bladder voiding difficulties longer than 10 days 81 (8 %), postoperative bowel paralysis longer than 7 days 80 (8.3 %), stoma complications 25 (2.6 %).

No.	Variable	Overall sample size	No. of centers	Statistics	Categories	Overall statistics	Range in statistics of centers	P value
1	Length of specimen (cm) <sup>a</sup>	956	10	Median		25.8	20–39	<.0001
2	Maximum height of mesocolon (cm) <sup>a</sup>	514	10	Median		9	6.5-12.5	<.0001
3	Number of lymph nodes examined	957	10	Median		16	9–24	<.0001
4	Lymph node ratio <sup>b</sup> in node-positive patients	395	10	Median		0.22	0.16-0.36	0.2431
5	Lymph node ratio <sup>b</sup> in node-positive patients without distant metastasis (UICC stage III)	269	10	Median		0.16	0.13–0.41	0.4014
6	Distance to nearer bowel resection margin in <i>colon</i> cancer (excl. rectosigmoid junction, cm)	495	10	Median		8	5-12	<.0001
7	Distance to nearer bowel resection margin in cancer of <i>rectosigmoid junction</i> (cm)	64	9	Median		4	3–5.5	0.6835
8	Distance to nearer bowel resection margin in <i>rectal</i> cancer (cm) <sup>a</sup>	372	9	Median		2.5	2–3	0.0133
9	Height of major artery ligation <sup>a</sup>	960	10	Proportion	High (central) Intermediate Low (peripheral)	0.71 0.25 0.04	0.40–0.97 0.02–0.53 0–0.15	<.0001

Table 3 Results regarding surgical radicality, analyzed as overall statistics and per each surgical department

Dept. surgical department, LN lymph nodes

<sup>a</sup> Patients with transanal local excision of rectal cancer are excluded from this analysis

<sup>b</sup> Lymph node ratio: proportion of positive LN among all LN examined

In a logistic regression model with center as stratification factor, a significant association between perioperative blood loss and need of blood transfusion was found (p < 0.001). An increase of 100-ml blood loss resulted in an odds ratio indicating a 1.11 times higher risk for a blood transfusion (95% confidence interval 1.06–1.16). Analyzing the association by center, the strongest associations were present in centers 3 and 4 (odd ratios 1.35 and 1.27).

#### **Rectal cancer**

Three hundred and eighty-four patients had primary rectal cancer defined as carcinoma of up to 15 cm from anal verge. Transanal local excision was performed in five patients (1.3 %), anterior resection in 312 patients (81.3 %), and abdominoperineal resection in 67 patients (17.4 %), resulting in an anal sphincter preservation rate of 82.6 %. Necessary mesorectal excision was done totally or longitudinally partially in 416 out of 445 patients (93.5 %) with carcinoma in the rectum or at the rectosigmoid junction. Of the 378 patients with carcinoma in the rectum or at the rectosigmoid junction who had anterior resection, a cytotoxic irrigation of the clamped rectum was performed in 277 patients (73.3 %) and the distal dissection site was completely within the irrigated section of the rectum in 263 patients (69.6 %). The additional resection of an involved distal resection margin was necessary in six patients (1.6 %) with rectal cancer. The anastomosis of the 312 patients with anterior resection for rectal cancer was protected by a temporary stoma in 199 patients (63.8 %). A leak of these anastomoses was encountered in 25 patients (8.0 %). An intra-abdominal or intrapelvic abscess was detected in 30 patients (7.8 %) of all rectal resections. Additional results regarding rectal cancer are listed in Table 2 (items 5, 6, 18, and 19), Table 3 (item 8), and Table 4 (items 5 and 11–14).

#### Influence of laparoscopic technique

Frequencies of the use of laparoscopic technique and conversion rates are mentioned in Table 2, items 15 and 16. The laparoscopically resected colorectal specimens were significantly shorter than the specimens of the open technique: given as medians 18 vs. 26 cm (p < 0.001). This was still true for the one center (center 9) with strong preference for the laparoscopic technique: 18 cm in laparoscopic and 25 cm in open technique. In 6 out of 7 centers performing laparoscopic resections for CRC, the median number of examined lymph nodes was smaller in the laparoscopic group. For the center with preference for the laparoscopic technique, the median number of lymph nodes was 16 in the laparoscopic group vs. 19 in the open group (p = 0.011), for node-positive patients in this center even 15 vs. 23.5 (p = 0.009). Interestingly, the median lymph node ratio (in node-positive patients) was smaller in the laparoscopic group than in the open group in this center (0.14 vs. 0.27, p = 0.094). Regarding the whole study population, other differences were noticed when comparing the laparoscopic versus the open technique: artery ligation before tumor mobilization in 83 vs. 66 %

No.	No. Variable	Overall sample No. of centers Statistics size	No. of centers	Statistics	Categories	Overall statistics	Range in statistics of centers	<i>P</i> value
	In-hospital mortality	965	10	Proportion		0.02	0-0.06	0.0395
2	In-hospital mortality following emergency colorectal resection	965	10	Proportion		0.005	0-0.03	0.0841
Э	Intra-abdominal septic complications (leak and/or abscess)	965	10	Proportion		0.07	0-0.17	0.0030
4	Reoperation	965	10	Proportion		0.08	0-0.17	0.0111
5	Abdominoperineal resection of rectal cancer	384	6	Proportion		0.17	0-0.30	0.1372
9	Perioperative blood loss (ml)	964	10	Median		300	200-500	<.0001
7	Patients needing perioperative blood transfusions	961	10	Proportion		0.19	0.05 - 0.40	<.0001
8	Perioperative blood loss for patients needing blood transfusion (ml)	180	10	Median		400	200 - 1000	0.0175
6	Tumors opened during mobilization	961	10	Proportion		0.05	0-0.11	0.0499
10	T4-tumors not en-bloc resected (% of T4)	121	6	Proportion		0.11	0-0.33	0.1272
11	Cytotoxic irrigations of anorectal stump (% of rectal and rectosigmoid cancers with anterior resection)	352	6	Proportion		0.79	0.14-1.0	0.0005
12	Principles of mesorectal excision applied (% of rectal and rectosigmoid cancers) <sup>a</sup>	445	6	Proportion		0.93	0.85-1.0	0.1226
13	Rectal cancer specimens with circumferential margin $\leq 1 \text{ mm}^a$	301	9	Proportion		0.10	0-0.19	0.1113
14	Minimum histological distance from rectal cancer to circumferential resection margin (mm) <sup>a</sup>	206	6	Median		8	3-17	0.0011
15	No-touch isolation technique	964	10	Proportion	Arterial ligature	0.67	0.36-0.86	<.0001
					Venous ligature	0.68	0.36-0.86	<.0001
					Closure of bowel lumen	0.50	0.13-0.92	<.0001
16	Iatrogenically perforated mesocolon/mesorectum <sup>a</sup>	958	10	Proportion		0.04	0-0.08	0.2691

 Table 4
 Results regarding oncosurgical quality, analyzed as overall statistics and per each surgical department

<sup>a</sup> Patients with transanal local excisions are excluded from this analysis

of patients (p = 0.002), vein ligation before tumor mobilization in 81 vs. 67 % (p = 0.008), closure of bowel lumen before tumor mobilization in 9 vs. 54 % (p < 0.001)), central ligature of main blood vessels in 84 vs. 70 % (p = 0.010). All other parameters regarding radicality or oncosurgical quality were similar between the laparoscopic and open technique.

#### Influence of colorectal emergency resections

Sixty-three patients had their CRC resected as an emergency, defined as resection within 24 h after emergency admission. The following most obvious differences between emergency and elective resections of CRC were detected: in-hospital death rate 7.9 vs. 2.1 % (p = 0.004), macroscopic residual tumor (R2-resections) 27.0 vs. 14.2 % (p = 0.006). Macroscopic residual tumor was locoregional only in 29.4 vs. 7.9 % (p = 0.019), and locoregional with or without distant disease in 35.3 vs. 18.3 % (p = 0.114), inadvertent tumor perforation 12.7 vs. 4.7 % (p = 0.013), central ligature of major artery 82.5 vs. 70.5 % (p = 0.041), UICC stage 3/4 59.7 vs. 44.1 % (p = 0.017), median length of specimen 38 vs. 25 cm (p < 0.001), median height of resected mesocolon 8 vs. 9 cm (p = 0.301), median number of examined lymph nodes 20 vs. 15 (p < 0.001), blood loss  $\ge$ 300 ml 69.8 vs. 56.8 % (p = 0.043).

## Influence of the presence of multiple primary colorectal carcinomas

Comparing the group of 39 patients suffering from multiple primary CRCs with the population with one primary CRC (n = 965), the following differences were found: median length of resected bowel for multiple CRC 35.0 vs. 25.8 cm for single CRC, in-hospital mortality 5.1 vs. 2.5 %, anastomotic leak/abscess 15.4 vs. 6.6 %, re-operation 18.4 vs. 8.4 %, median blood loss 500 vs. 300 ml, and need for perioperative blood transfusion 26.3 vs. 18.7 %.

#### Discussion

In the past, many studies dealing with the outcome of surgical management in patients with CRC have been published. We have learned that satisfying results may depend on special training and sufficient annual case load in this type of surgery. However, it is still not yet clear which specific features make the difference between poor and excellent CRC surgery in daily practice. Therefore, from a public health point of view, benchmarking is needed. One may suppose that each surgical department and each multidisciplinary team would like to know how their quality of treatment compares with population-based or multicenter data on nonselected consecutive patients. To achieve this goal, reliable data from audits in large numbers of consecutive patients are required. To facilitate the comparison between centers, the selection of patients, the surgical treatment, the pathological work-up of the specimen as well as the outcome should be assessed in a standardized manner. This will allow the identification of high standards of performance, which should be the aim of each center. The knowledge of the benchmark and the average performance should motivate each center to improve its performance and to get as close as possible to or beyond the benchmark.

This study allowed us to assess prospectively—in detail and in a standardized manner—the surgical radicality and the oncosurgical quality of the specimens of patients with CRC from ten centers.

Although each center claimed to have special interest and expertise in CRC surgery, noteworthy differences in surgical radicality between different centers were detected. For example, the median lengths of the colorectal specimens varied from 20 to 40 cm between centers. To avoid any bias from different measuring conditions—the length of a stretched and natively measured colorectal specimen can shrink by up to 57 % in an unstretched and formaline-fixed state [18–20]—the pathologists of each center had to declare the measuring condition for each specimen on a standardized pathology form. In every center, at least 79 % of all specimens had been measured without tension and after formaline fixation; thus, the differences in median specimen lengths seem to reflect reality.

Increasing the length of colorectal specimens goes along with increasing number of harvested lymph nodes [21]. And a total number of lymph nodes  $\geq 12$  significantly improved the 5-year survival to 51 % in stage III colon cancer, compared with 45 % in patients with less than 12 lymph nodes examined [22]. Furthermore, the total number of examined lymph nodes seems to play an important prognostic role even in node negative patients [23, 24]. Thus, for the 648 node negative patients of the Intergroup Trial INT-0089 (trial of adjuvant chemotherapy for high-risk patients with stage II and stage III colon cancer) overall survival and cause-specific survival both increased significantly with the increasing number of analyzed lymph nodes [23]. In the present series, the median number of analyzed lymph nodes was 16 and compared well with other large series that revealed medians of less than 12 lymph nodes [22, 25, 26]. The rather high number of lymph nodes in the present series may reflect the adequate length of specimens, the adequate amount of mesocolon resected, or both, always assuming careful pathological examination. However, important differences were detected again between different centers ranging from a median of 9 lymph nodes retrieved to 24, although none of the pathology institutes used a fat clearance technique to detected small differences in percentages of stage IV cancers or of neoadjuvant treatment are unlikely to explain the differences in examined lymph nodes between the centers.

Some authors promote the use of the lymph node ratio (LNR), i.e., the quotient of metastatic over total number of lymph nodes, as a predictor for prognosis rather than the total number of retrieved lymph nodes [22, 27–29]. This might especially be true for LNRs of  $\geq 0.25$  [22, 27, 30], indicating more advanced tumors, insufficient surgery, or both. Although we detected variable LNRs in our study, ranging from LNR values of 0.16 to 0.31, the rather low LNRs may again represent the relatively high radicality of surgery in the participating centers.

We postulate that another indicator of surgical radicality is the length of resected mesocolon, measured along the main artery from its central tie up to the bowel wall. Since almost all of the intermediate and central lymph nodes are found along the primary feeding arteries, as well as potential lymph node metastasis in those, central dissection of colonic arterial trunks seems to have prognostic relevance, especially for T3-T4 tumors, and even for T2 tumors that are sited in lengthening of the primary feeding artery [31]. To our knowledge, this is the first study that prospectively assessed the exact ligation level of the (primary) feeding artery/arteries and the height of resected mesocolon (i.e., the length of mesocolon perpendicularly measured to the colonic axis) as surrogate marker of central lymph node dissection. Further, this is the first study that demanded of the surgeons to mark the tumor site and the resection margins (bowel, blood vessels) in a standardized figure instead of a sole description of the surgical procedure. The intent of this measure was to minimize the well known discrepancies in anatomical nomenclature and in understanding of surgical anatomy between surgeons and to facilitate final analysis at the SAKK coordinating center. The 72 % overall rate of central ligation of primary feeding arteries seems to demonstrate that the participating surgeons were aware of the importance of this surgical step. Still, the percentages of specimens with central artery ligation differed between 39 and 97 % between centers. Accordingly, we observed a rather wide variation in median mesocolon lengths between centers, ranging from 6.5 to 12.0 cm. In a recent retrospective analysis of 399 specimens of resected colonic cancers. Ouirke and colleagues noted a mean distance of 4.4 cm from the muscularis propria to the mesocolic resection margin in the best of their three groups, adding, however, that a high vascular tie close to the aorta or the superior mesenteric artery had never been done at their institution [32]. Although not proven in a prospective randomized trial, several papers indicate that more complete mesocolic excision and higher artery ligation in colon cancer result in a cancer-related 5-year survival advantage of 6-15 % [23, 32-35].

The distance of the tumor to the nearer bowel margin was of further interest as even a long specimen does not guarantee a priori adequate bowel margins on both sides. Excluding rectal cancer specimens, the median distances to the nearer bowel margin varied from 5.5 to 12.0 cm in the present series. Depending on the T-stage, a safety margin of 5.5 cm seems to be critical since pericolic lymph node metastasis up to 7 cm away from the primary occurs in 4 % [31], and more than 10 cm in 0.9–2.0 % [31, 36, 37].

Surgeons performing colorectal resection for cancer should precisely dissect along the mesenteric or mesorectal plane to avoid opening of the compartment of potential lymphatic spread [32, 33] and of mesenteric blood vessels. If this is done, and if no other accidental damage occurs, the expected blood loss is usually small. Therefore, the median blood loss and the need for perioperative blood transfusions seem to be indicators for oncosurgical quality and the surgeons' expertise and have been reported as prognostic factors [38]. Indeed, we found at least a tendential correlation between the average blood loss and the overall surgical performance per center, as well as between the number of patients needing blood transfusions and the overall surgical performance, as depicted in Table 4.

We noted a rather large variation in abdominoperineal resection (APR) rates, ranging from 6.3 to 29.6 %, between the eight centers treating patients with rectal cancers at all heights. Similarly, analysis of 31,223 patients receiving a major abdominal procedure for rectal cancer within the NHS in England between 1998 and 2004 revealed extensive and highly significant variation across hospital trusts with APR rates varying from 8.5 to 52.6 %, independently on patient case mix. Although the APR rate decreased from 30.5 % in 1998 to 23.0 % in 2004 in that study, the authors conclude that this variation in APR rates is unacceptable and that rates of APR use could be a national performance measure [39]. The same is true for the APR rates in our series.

Interestingly, all centers had a few patients in whom inadvertent tumor opening occurred although some centers seemed to resect T4 tumors strictly en-bloc with parts of infiltrated neighboring organs. It is the first author's experience that inadvertent tumor opening may be difficult to avoid if covered tumor perforation to the pelvic side wall or the retroperitoneum is present. Several previous studies showed a significant reduction of the overall 5-year survival rate in patients with inadvertent tumor perforation, ranging from 20 to 26 % [40–42]. Therefore, inadvertent tumor perforation and the consecutive tumor cell spillage are adverse prognostic factors, and hence in some cases, another feature of oncosurgical quality.

Interpretation of morbidity and mortality in surgical oncology is delicate since more radical and more precise resections may be prone to more perioperative morbidity due to increased operating times and due to more demanding procedures. Therefore, morbidity, mortality, and re-operation rate of CRC surgery have to be evaluated for each center in context with case mix and with indicators of the center-specific surgical radicality and oncosurgical quality. The various treatment policies for emergencies due to CRC might further have influenced the center-specific mortality and morbidity rates in this series since only patients with tumor resection were included.

For rectal cancer, a high standard of surgical therapy with only small differences between the centers was found. Almost without exception, the technique of total or longitudinally partial excision of the mesorectum was applied by all centers and all surgeons. The median distal resection margin of at least 2.4 cm, measured without tension and after formaline fixation, in 8 out of 9 centers revealed reasonable surgical quality. All centers showed less than 15 % of rectal cancer specimens with a circumferential resection margin of <1 mm. It seems that the global efforts to propagate the TMEtechnique contributed to the fact that TME is now accepted in Switzerland and has been adopted as standard surgical procedure for rectal cancers [43-45]. Correspondingly, the prognosis for rectal cancer in Sweden has improved substantially and is now at least equal to the prognosis of colon cancer. Our study contributes to the identification of the surgical details in colon cancer that are crucial to improve the prognosis, similarly to what has been done for rectal cancer [6, 7, 42, 43]. Therefore, the long-term results of this study and especially the correlation of the long-term results with the issues of radicality and oncosurgical quality will be of interest.

Overall, the causes of the rather wide variations in radicality and oncosurgical quality between the centers remain speculative. Since 8 out of 10 centers have similar services, structural or process factors are unlikely to be responsible for the detected wide differences. Furthermore, largely differing case-mixes did not have been found as other possible explanation of the variations between the centers. Therefore, the crucial factors for the different radicalities and oncosurgical qualities seem to be the surgeons themselves or the specific surgical concepts of the different centers.

The following suggestions may be proposed to improve the performance of every surgeon and every surgical institution: meticulous anatomical knowledge by the surgeons is crucial, not only to identify and remove the important vascular and lymphatic structures but also to name them in the reports. Standardization of the surgical technique using a standardized procedure protocol and objective measuring tools is mandatory. And, standardization of the pathology work-up according to (future) guidelines will give the necessary feedback about the surgeons' performance. Supervision by regular audits may be an additional tool of quality control and may form the base for continuing improvement. Regular visits of workshops and life operations in highly specialized centers for colorectal cancer surgery are also recommended. Further, systematic long-term follow-up of the patients with careful analysis of potential reasons for tumor relapse should be declared obligatory.

#### Conclusions

The results obtained by the participating centers in Switzerland and Germany compare well with other series. The results may reflect the reality in CRC surgery, still far away from being satisfactory. Comparing the different centers, the top results for each single issue of radicality and oncosurgical quality may now serve as benchmarks for all other centers. The impressive differences in radicality and oncosurgical quality between the centers revealed that most of the centers still have a large potential for improvement.

Acknowledgments We thank the co-workers of the pathology institutes of Liestal, Chur, Bern, Zürich, Luzern, all in Switzerland, and of Homburg-Saar, Germany, for their excellent collaboration in examination of all the colorectal specimens in a standardized manner and in completing the pathology forms. Furthermore, we thank Mr. Michael Mayer and Mrs. Hong Sun for the statistical support and Mrs. E. Hansen and L. Kacina for data collection, all from the SAKK Coordinating Center in Bern. The study was financially supported by the Swiss State Secretariat for Education and Research (SER).

No.	Variable	Statistics	Total	Dept1	Dept2	Dept3	Dept4	Dept5	Dept6	Dept7	Dept8	Dept9	Dept10	P value
0	Evaluable patients with	Sample size	965	92	12	163	204	62	13	66	178	97	45	
1	Age (years)	Median Min Max	70 21 100	73 33 94	76 61 83	71 27 89	67 34 90	66 44 90	63 48 82	72 42 93	72 21 100	72 33 92	71 29 88	<.0001
0 0	Female sex	Frequency Proportion	378 0.39	37 0.40	5 0.42	55 0.34	74 0.36	21 0.34	6 0.46	39 0.39	74 0.42	49 0.51	18 0.40	0.3933
n	ADA SCOTE 1 3	Proportion Proportion Proportion	0.13 0.56 0.29	0.07 0.58 0.33	0.25 0.58 0.17	0.10 0.67 0.22	0.07 0.55 0.36	0.29 0.47 0.23	0.31 0.54 0.15	0.08 0.47 0.39	$\begin{array}{c} 0.19\\ 0.57\\ 0.22\end{array}$	0.13 0.47 0.32	0.18 0.51 0.29	0.0005
4	4-5 Body mass index (kg/m <sup>2</sup> )	Proportion Median Min May	0.02 25.4 14.7 51.7	0.03 25.4 17.8 51.7	0 26.4 19.4 40.3	0.01 25.3 16.5 37.6	0.01 26.2 14.7 41.6	0.02 24.5 18.2 40.4	0 24.1 18.0 34.9	0.0 26.1 16.7 41 8	0.02 24.4 15.6 30.8	0.07 25.0 15.6 41.0	0.02 25.4 18.7 37.3	0.0079
5	Patients with rectal cancer	Frequency Proportion	384 0.40	37 0.40	5 0.42	57 0.35	109 0.53	27 0.44	00	23 0.23	83 0.47	28 0.29	15 0.33	<.0001
9	Rectal cancers treated with neoadjuvant radiotherapy	Sample size Frequency Proportion	384 106 0.28	37 10 0.27	5 3 0.60	57 5 0.09	109 16 0.15	27 17 0.63	0	23 5 0.22	83 37 0.45	28 8 0.29	15 5 0.33	<.0001
L	T-stage 0 + is 2 3	Sample size Proportion Proportion Proportion	964 0.02 0.18 0.18 0.58	92 0 0.05 0.17 0.65	12 0 0.42 0.58	163 0.05 0.17 0.17	203 0.01 0.15 0.24 0.57	62 0.06 0.16 0.16 0.53	13 0 0.15 0.08 0.54	99 0.01 0.09 0.15 0.59	178 0.01 0.04 0.20 0.61	97 0.04 0.11 0.09 0.55	45 0.04 0.09 0.09	0.0004
×	4 N-stage 0 1	Proportion Sample size Proportion Proportion	0.13 960 0.58 0.21	0.12 89 0.61 0.17	0 12 0.67 0.08	0.15 161 0.51 0.29	0.03 204 0.58 0.23	0.08 62 0.63 0.16	0.23 13 0.62 0.15	0.16 99 0.59 0.20	$\begin{array}{c} 0.14 \\ 178 \\ 0.59 \\ 0.18 \end{array}$	0.21 97 0.63 0.22	0.22 45 0.56 0.20	0.7917
6	2 M-stage 0 1	Proportion Sample size Proportion Proportion	0.21 964 0.83 0.17	0.22 92 0.84 0.16	0.25 12 0.92 0.08	0.20 163 0.80 0.20	0.19 204 0.82 0.18	0.21 62 0.90 0.10	0.23 13 0.92 0.08	0.21 99 0.77 0.23	$\begin{array}{c} 0.23\\ 177\\ 0.86\\ 0.14\end{array}$	0.15 97 0.86 0.14	0.24 45 0.82 0.18	0.4386

🙆 Springer

(continue
S
ble

Table	Table 5 (continued)													
No.	Variable	Statistics	Total	Dept1	Dept2	Dept3	Dept4	Dept5	Dept6	Dept7	Dept8	Dept9	Dept10	P value
10	UICC-stage 0 I	Sample size Proportion Proportion	959 0.02 0.22	89 0 0.16	12 0 0.42	161 0.04 0.18	204 0.01 0.31	62 0.05 0.29	$\begin{array}{c} 13\\ 0\\ 0.23 \end{array}$	99 0.01 0.20	$\begin{array}{c} 177\\ 0.01\\ 0.20\end{array}$	97 0.03 0.16	45 0 0.11	0.0166
		Proportion	0.31	0.25	0.25	0.25	0.22 0.28	0.27	0.38 0.31	0.32	0.35	0.40	0.40	
11	IV Grading 1–2	Proportion Sample size Proportion	0.17 930 0.76	0.17 86 0.81 0.10	0.08 12 0.92	0.20 159 0.77	0.18 192 0.55	0.10 59 0.90	0.08 13 0.77	0.23 97 0.84 0.16	0.14 175 0.82 0.18	0.14 94 0.76	0.18 43 0.81 0.19	<.0001
12	Maximum diameter of primary (cm)	Sample size Median Min	922 4 0	89 4.5 0.2	0.00 3.5 2.5	0.2 4 0.3 12	0.1 194 3 0.1	0.10 60 0 12	1 4 13	91.0 84 0 31	178 4 0	67 9 0 1 0	0.17 0 14	<.0001
13	Specimens measured after formaline fixation	Sample size Frequency Proportion	961 862 0.90	92 92 71 0.77	12 12 1.0	12 163 132 0.81	203 197 0.97	62 61 0.98	13 13 13	99 95 0.96	17. 177 143 0.81	12 95 1.0	45 43 0.96	<.0001
14	Patients operated by laparoscopy	Frequency Proportion	80 0.08	2 0.02	4 0.33	6 0.04	1 0.00	0 0	0 0	1 0.01	3 0.02	63 0.65	0 0	<.0001
15	Conversion to open operation	Sample size Frequency Proportion	80 10 0.13	2 1 0.50	400	6 1 0.17	1 0 0	0	0	1 0 0	ю 0 ж	63 8 0.13	0	0.5948
16 17	Emergency large bowel resection Stoma formation in	Frequency Proportion Sample size	63 0.07 581	15 0.16 55	00 2	9 0.06 106	$\begin{array}{c}3\\0.01\\95\end{array}$	0 35	0 0	11 0.11 76	17 0.10 95	6 0.06 69	2 0.04 30	<.0001 0.1960
18	colon cancer patients Stoma formation in	Frequency Proportion Sample size	28 28 0.05 384	2 0.04 37	, 0 0 v	0.08 57	9 0.09 109	1 0.03 27	000	0.01 23	3 0.03 83	2 0.03 28	1 0.03 15	0.0001
	rectal cancer patients	Frequency Proportion	265 0.69	27 0.73	4 0.80	45 0.79	85 0.78	21 0.78		8 0.35	52 0.63	14 0.50	9 0.60	
19	Distance of rectal cancers from anal verge (cm)	Sample size Median Min Max	384 7 0 15	37 8 15	5 8 4 4 1	57 7 1 15	109 6 15	27 6 1 14	0	23 9 15	83 6 15	28 9 14	15 11 3 14	0.0234
The s <sup>6</sup> tests fo	The sample sizes for a variable are given only if it differs from the overall sample sizes in No. 0. <i>P</i> values: chi-square tests for frequencies, Monte Carlo approximation for low frequencies; Kruskal-Wallis tests for measurements (summarized by median, min, max). Missing items excluded from analyses	y if it differs from lian, min, max). N	the overall s Aissing items	ample sizes s excluded	verall sample sizes in No. 0. $P$ v g items excluded from analyses	values: chies	square tests	for frequen	cies, Monte	Carlo appro	ximation fo	ır low frequ	encies; Krush	cal-Wallis

Dept. surgical department, ASA American Society of Anesthesiology, UICC International Union Against Cancer

	No.	Variable	Statistics	Total	Dept1	Dept2	Dept3	Dept4	Dept5	Dept6	Dept7	Dept8	Dept9	Dept10	P value
Length of spectrum (on $j^{*}$ Sample size between (on $j^{*}$ Sample size be	0	Evaluable patients with one tumor location	Sample size	965	92	12	163	204	62	13	66	178	76	45	Ι
$\label{eq:main length} Maximum height of trescoolen (cm)^4 \\ Max \\ Max$	-	Length of specimen (cm) <sup>a</sup>	Sample size	956 25.8	89 30	12 25 5	161 26	202 25	62 77	13	99 33	178 22	97 00	43 22	<.0001
$\label{eq:matrix} Maximun bright of mesocolon (cm)* Max i (60 i i (60 i (50 i (5 i (5 i (7 7 i (5 i (5 i (7 i (5 i (5$			Min	8.5	13	13	11	8.5	11	11.2	13		9.5	12	
$ \begin{array}{llllllllllllllllllllllllllllllllllll$			Max	160	160	52	154	140	50	30	120	95	65	09	
	7	Maximum height of mesocolon (cm) <sup>a</sup>	Sample size	514	55	6	17	76	42	8	98	177	21	14	<.0001
Min         1 $2.5$ 3         4         3         3         6         1         1/3         1/3         3/3           Nurber of lymph nodes examined         Max         14         10         16         24         16         15         13         9         13         13         13         15         3           Min         0         7         6         1         13         3			Median	6	12.2	7.5	6	6	8.3	8	10	7	6.5	12.5	
Max         44         44         10         26         42         22         16         31         18         15         17           Number of lymph nodes examined         Main         0         7         6         3         0         0         4         2         3         2           Min         0         7         6         3         0         0         4         2         3         2           Min         0         7         6         3         0         0         0         4         2         3         2         3         2           Max         78         60         34         48         37         39         35         7         3         2         3         2         3         2         3         13         13         0         0         0         0         10         0         10         0         14         44         0         0         14         3         3         3         3         3         3         3         3         2         3         13         18         15         17         18         10         10         10         10			Min	1	2.5	Э	4	Э	ŝ	9	1	1.5	1.7	3.5	
			Max	44	44	10	26	42	22	16	31	18	15	17	
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	З	Number of lymph nodes examined	Sample size	957	88	12	161	203 10	62	13	66	178	96 2;	45	<.0001
Min         0         7         6         3         0         0         7         6         3         1         2         3         2           Lymph node ratio* in node-positive patients         Sample size         39         5         7         3         5         7         3         5         3         3         1           Lymph node ratio* in node-positive patients         Sample size         303         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.02         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.02         0.04         0.03         0.04         0.03         0.02 <td></td> <td></td> <td>Median</td> <td>10</td> <td>74</td> <td>10</td> <td>ci i</td> <td>13</td> <td>, ک</td> <td>17</td> <td>19</td> <td>cl -</td> <td>1/</td> <td>18</td> <td></td>			Median	10	74	10	ci i	13	, ک	17	19	cl -	1/	18	
Max         78         60         34         48         37         39         35         78         52         54         31           Lymph node ratio <sup>b</sup> in node-positive patients         Sample size         395         34         4         78         84         23         5         19         1           Lymph node ratio <sup>b</sup> in node-positive patients without         Sample size         395         34         4         78         84         23         51         10         100         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.03         0.04         0.03         0.04         0.03         0.03         0.03         0.04         0.03         0.04         0.03         0.03         0.04         0.03         0.04         0.03         0.03         0.03         0.03         0.04         0.03         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04			Min	0	7	9	ŝ	0	0	0	4	7	ŝ	7	
			Max	78	60	34	48	37	39	35	78	52	54	31	
Median         0.22         0.14         0.25         0.14         0.25         0.11         0.21         0.21         0.21         0.21         0.21         0.21         0.21         0.21         0.21         0.22         0.16         0.21         0.21         0.22         0.16         0.22         0.16         0.22         0.04         0.03         0.06         0.04         0.03         0.06         0.03         0.07         0.03         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.02         0.03         0.04         0.03         0.02         0.01	4	Lymph node ratio <sup>b</sup> in node-positive patients	Sample size	395	34	4	78	84	23	5	41	72	35	19	0.2431
Min         0.02         0.03         0.04         0.03         0.06         0.04         0.03         0.02         0.03         0.04         0.03         0.02         0.02         0.02         0.02         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.05         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.05         0.04         0.03         0.04         0.03         0.05         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.05         0.04         0.03         0.05         0.04         0.03         0.05         0.04         0.03         0.04         0.03         0.03         0.04         0.03         0.04         0.03         0.03         0.04         0.03         0.03         0.04         0.03         0.03         0.04         0.03         0.03         0.04         0.03         0.04         0.03         0.03         0.04         0.03         0.03         0.04         0.03         0.03         0.04         0.03         0.03 <th< td=""><td></td><td></td><td>Median</td><td>0.22</td><td>0.16</td><td>0.36</td><td>0.18</td><td>0.25</td><td>0.31</td><td>0.31</td><td>0.21</td><td>0.29</td><td>0.16</td><td>0.21</td><td></td></th<>			Median	0.22	0.16	0.36	0.18	0.25	0.31	0.31	0.21	0.29	0.16	0.21	
			Min	0.02	0.03	0.04	0.03	0.03	0.06	0.04	0.03	0.02	0.02	0.04	
			Max	1.00	1.00	0.55	1.00	1.00	1.00	0.51	0.88	1.00	0.88	1.00	
distant metastasis (UICC stage III)         Median         0.16         0.14         0.11         0.12         0.15         0.28         0.25         0.17         0.20         0.15         0.17         0.20         0.15         0.15         0.17         0.20         0.15         0.15         0.17         0.20         0.02         0.02         0.03         0.04         0.03         0.02         0.03         0.04         0.03         0.02         0.03         0.04         0.03         0.02         0.03         0.04         0.03         0.02         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.02         0.04         0.03         0.04         0.03         0.02         0.03         0.04         0.03         0.02         0.03         0.04         0.03         0.02         0.03         0.04         0.03         0.02         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.02         0.05         0.04         0.03         0.04         0.03         0.05         0.04         0.03         0.04         0.03         0.04         0.03         0.04         0.03         0.04 <td>5</td> <td>Lymph node ratio<sup>b</sup> in node-positive patients without</td> <td>Sample size</td> <td>269</td> <td>22</td> <td>3</td> <td>51</td> <td>57</td> <td>18</td> <td>4</td> <td>23</td> <td>52</td> <td>25</td> <td>14</td> <td>0.4014</td>	5	Lymph node ratio <sup>b</sup> in node-positive patients without	Sample size	269	22	3	51	57	18	4	23	52	25	14	0.4014
$ \begin{array}{llllllllllllllllllllllllllllllllllll$		distant metastasis (UICC stage III)	Median	0.16	0.14	0.41	0.12	0.15	0.28	0.25	0.17	0.20	0.15	0.17	
$ \begin{array}{cccccc} Max & 1.00 & 0.79 & 0.55 & 0.87 & 1.00 & 1.00 & 0.51 & 0.58 & 1.00 & 0.54 & 0.50 \\ \hline \mbox{Distance to nearer bowel resection margin in Sample size } 495 & 48 & 6 & 90 & 80 & 27 & 13 & 71 & 82 & 58 & 20 \\ \hline \mbox{colon cancer (excl. Rectosigmoid junction, cm)} & Min & 0 & 0 & 3 & 0.5 & 0.5 & 1.5 & 2.2 & 1.5 & 1.1 \\ \hline \mbox{Max} & 46 & 19 & 10 & 29 & 27 & 20 & 15.5 & 41.5 & 46 & 17 & 22 \\ \hline \mbox{Distance to nearer bowel resection margin in Sample size } 64 & 7 & 1 & 14 & 10 & 5 & 0 & 4 & 13 & 5 & 5 \\ \hline \mbox{matrix to nearer bowel resection margin in Sample size } 64 & 7 & 1 & 14 & 10 & 5 & 0 & 4 & 13 & 5 & 5 \\ \hline \mbox{matrix to nearer bowel resection margin in Sample size } 64 & 7 & 1 & 14 & 10 & 5 & 0 & 4 & 13 & 5 & 5 \\ \hline \mbox{matrix to nearer bowel resection margin in Sample size } 64 & 7 & 1 & 14 & 10 & 5 & 0 & 4 & 13 & 5 & 5 \\ \hline \mbox{matrix to nearer bowel resection margin in Sample size } 64 & 7 & 1 & 14 & 10 & 5 & 0 & 4 & 13 & 5 & 5 \\ \hline \mbox{matrix to nearer bowel resection margin in Sample size } 372 & 3.3 & 5 & 2 & 0 & 27 & 20 & 15 & 2 & 2 & 4 \\ \hline \mbox{matrix to nearer bowel resection margin in Sample size } 372 & 33 & 5 & 2 & 0 & 2 & 7 & 6 & 9 & 9 & 16 & 2 & 7 & 6 & 8 & - & 8 & 1.5 & 2 & 2 & 2 \\ \hline \\mbox{matrix to nearer bowel resection margin in Sample size } 372 & 33 & 5 & 2 & 0 & 2 & 7 & 6 & 9 & 0 & 0 & 0 & 0 \\ \hline \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\$			Min	0.02	0.03	0.04	0.03	0.03	0.06	0.04	0.03	0.02	0.02	0.04	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			Max	1.00	0.79	0.55	0.87	1.00	1.00	0.51	0.58	1.00	0.54	0.50	
$\overline{colon}$ cancer (excl. Rectosignoid junction, cm)         Median         8         9.5         5.8         8         6         5         6.5         12         7         6         7.3           Min         0         0         3         0.5         0.5         1.5         2         1.5         1.5         1.1           Max         46         19         10         29         27         20         15.5         41.5         46         17         22           Distance to nearer bowel resection margin in         Sample size         64         7         1         14         10         5         0         4         3         5.5         17         22         14         3         3.5         -         4.8         4         3         5.5         5 <t< td=""><td>9</td><td>Distance to nearer bowel resection margin in</td><td>Sample size</td><td>495</td><td>48</td><td>9</td><td>06</td><td>80</td><td>27</td><td>13</td><td>71</td><td>82</td><td>58</td><td>20</td><td>&lt;.0001</td></t<>	9	Distance to nearer bowel resection margin in	Sample size	495	48	9	06	80	27	13	71	82	58	20	<.0001
Min         0         0         3         0.5         0.5         1.5         2         1.5         2.1         1.1           Max         46         19         10         29         27         20         15.5         41.5         46         17         22           Cancer of rectosignoid junction (cm)         Macdian         4         5.5         3.5         4         3.3         3.5         -         4.8         4         3         5.5         5           Cancer of rectosignoid junction (cm)         Median         4         5.5         3.5         4         3.3         3.5         -         4.8         4         3         5.5         5           Min         0.5         2.1         -         2         0.7         -         3         1.5         2.7         4           Distance to nearer bowel resection margin in         Sample size         372         33         5         5         5         5           Distance to nearer bowel resection margin in         Sample size         372         33         5         5         5         5         5         5         5         5         5         5         5         5         5		colon cancer (excl. Rectosigmoid junction, cm)	Median	8	9.5	5.8	8	9	S	6.5	12	7	9	7.3	
$ \begin{array}{llllllllllllllllllllllllllllllllllll$			Min	0	0	3	0.5	0.5	1.5	2	1.5	2.2	1.5	1.1	
Distance to nearer bowel resection margin in cancer of rectosigmoid junction (cm)Sample size $64$ $7$ $1$ $14$ $10$ $5$ $0$ $4$ $13$ $5$ $5$ cancer of rectosigmoid junctionMedian $4$ $5.5$ $3.5$ $4$ $3.3$ $3.5$ $ 4.8$ $4$ $3$ $5.5$ Min $0.5$ $2.1$ $ 2$ $0.5$ $0.7$ $ 4.8$ $4$ $3$ $5.5$ Min $0.5$ $2.1$ $ 2$ $0.5$ $0.7$ $ 3$ $1.5$ $2$ $4$ Distance to nearer bowel resection margin in rectal cancer, <u>only</u> (cm) <sup>a</sup> Max $9$ $6$ $ 7$ $6$ $8$ $ 6$ $9$ $8$ $-$ Min $0$ $0.5$ $0.4$ $0.2$ $0.7$ $0$ $2.3$ $83$ $27$ $15$ $-$ Meidian $2.5$ $3$ $2$ $2.2$ $2.2$ $2.2$ $2.2$ $2.2$ $2.2$ $2.8$ Min $0$ $0.5$ $0.4$ $0.2$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ Height of major arteryMax $14$ $8$ $4$ $8.5$ $7$ $6$ $ 8$ $12$ $14$ $9$ Height of major artery $14$ $8$ $12$ $161$ $204$ $62$ $13$ $9$ $178$ $97$ $45$			Max	46	19	10	29	27	20	15.5	41.5	46	17	22	
cancer of rectosignoid junction (cm)       Median       4       5.5       3.5       4       3.3       3.5       -       4.8       4       3       5.5         Min $0.5$ $2.1$ $ 2$ $0.5$ $0.7$ $ 3$ $1.5$ $2$ $4$ Distance to nearer bowel resection margin in       Sample size $372$ $33$ $5$ $53$ $106$ $27$ $0$ $23$ $83$ $27$ $15$ $15$ Distance to nearer bowel resection margin in       Sample size $372$ $33$ $5$ $53$ $106$ $27$ $0$ $23$ $83$ $27$ $15$ $15$ rectal cancer, $only (cm)^a$ Min $0$ $0.5$ $0.4$ $0.2$ $0$	7	Distance to nearer bowel resection margin in	Sample size	64	7	1	14	10	5	0	4	13	5	5	0.6835
Min $0.5$ $2.1$ $ 2$ $0.5$ $0.7$ $ 3$ $1.5$ $2$ $4$ Max $9$ $6$ $ 7$ $6$ $8$ $ 3$ $1.5$ $2$ $4$ Distance to nearer bowel resection margin in       Sample size $372$ $33$ $5$ $53$ $106$ $27$ $0$ $2$ $2$ $4$ Distance to nearer bowel resection margin in       Sample size $372$ $33$ $5$ $53$ $106$ $27$ $0$ $2$		cancer of rectosigmoid junction (cm)	Median	4	5.5	3.5	4	3.3	3.5	Ι	4.8	4	б	5.5	
Max       9       6       -       7       6       8       -       6       9       8       6         Distance to nearer bowel resection margin in rectal cancer, only (cm) <sup>a</sup> Sample size       372       33       5       53       106       27       0       23       83       27       15       15         rectal cancer, only (cm) <sup>a</sup> Median       2.5       3       2       2.2       2.2       2.2       2.3       3       3       2.2       2.8       15       16         Min       0       0.5       0.4       0.2       0       0       0       0       0       0       0       14       8       4       8.5       7       6       -       8       12       14       9         Height of major artery       Max       14       8       4       8.5       7       6       -       8       12       14       9       17       9       17       9       17       9       17       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45       45 <td< td=""><td></td><td></td><td>Min</td><td>0.5</td><td>2.1</td><td>Ι</td><td>2</td><td>0.5</td><td>0.7</td><td>Ι</td><td>б</td><td>1.5</td><td>2</td><td>4</td><td></td></td<>			Min	0.5	2.1	Ι	2	0.5	0.7	Ι	б	1.5	2	4	
Distance to nearer bowel resection margin in       Sample size $372$ $33$ $5$ $53$ $106$ $27$ $0$ $23$ $83$ $27$ $15$ rectal cancer, $only$ (cm) <sup>a</sup> Median $2.5$ $3$ $2$ $2.2$ $2.2$ $2$			Max	6	9	I	7	9	8	I	9	6	8	9	
rectal cancer, $only$ (cm) <sup>a</sup> Median $2.5$ $3$ $2$ $2.8$ Min       0       0.5       0.4       0.2       0	8	Distance to nearer bowel resection margin in	Sample size	372	33	5	53	106	27	0	23	83	27	15	0.0133
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		rectal cancer, <u>only</u> (cm) <sup>a</sup>	Median	2.5	З	2	2.2	2.2	2	I	3	б	2.2	2.8	
Max         14         8         4         8.5         7         6         -         8         12         14         9           Height of major artery         Sample size 960         89         12         161         204         62         13         99         178         97         45         -         45         -         56         -         56         -         56         -         56         56         56         50         50         178         97         45         -         -         56         -         -         50         178         97         -         56         -         -         50         178         97         -			Min	0	0.5	0.4	0.2	0	0	I	0.9	0	0	0	
Height of major artery Sample size 960 89 12 161 204 62 13 99 178 97 45 .			Max	14	8	4	8.5	7	9	Ι	8	12	14	9	
Sample size 960 89 12 161 204 62 13 99 178 97 45	6	Height of major artery													
		ligation:	Sample size	096	89	12	161	204	62	13	66	178	76	45	<.0001

🖄 Springer

(continued)
9
Table

Deringer

No.	No. Variable	Statistics	Total	Dept1	Dept2	Dept3	Dept4	Dept5	Dept6	Dept7	Dept8	Dept9	Dept10	P value
	- high (central)	Proportion	0.71	0.90	0.92	0.47	0.82	0.40	0.61	0.97	0.65	0.80	0.60	
	- intermediate	Proportion	0.25	0.10	0.08	0.48	0.16	0.53	0.23	0.02	0.30	0.11	0.31	
	- low (peripheral) <sup>a</sup>	Proportion	0.04	0	0	0.04	0.02	0.06	0.15	0.01	0.04	0.08	0.09	
		:								.			}	

The sample sizes for a variable are given only if it differs from the overall sample sizes in No. 0. *P* values: chi-square tests for frequencies, Monte Carlo approximation for low frequencies; Kruskal-Wallis tests for measurements (summarized by median, min, max). Missing items excluded from analyses

Dept. surgical department, LN lymph nodes

<sup>a</sup> Patients with transanal local excision of rectal cancer are excluded from this analysis

<sup>b</sup> Lymph node ratio: proportion of positive LN among all LN examined

			I		I									
No.	Variable	Statistics	Total	Dept1	Dept2	Dept3	Dept4	Dept5	Dept6	Dept7	Dept8	Dept9	Dept10	P value
0	Evaluable patients with one tumor location	Sample size	965	92	12	163	204	62	13	66	178	67	45	I
1	In-hospital mortality	Frequency Proportion	24 0.02	5 0.05	0 0	9 0.06	$2 \\ 0.01$	0 0	0 0	0 0	2 0.01	4 0.04	2 0.04	0.0395
7	In-hospital mortality following emergency colorectal resection	Frequency Proportion	5 0.005	3 0.03	0 0	$2 \\ 0.01$	0 0	0 0	0 0	0 0	0 0	0 0	0 0	0.0841
ŝ	Intra-abdominal septic complications (leak and/or abscess)	Frequency Proportion	64 0.07	3 0.03	2 0.17	4 0.02	$19 \\ 0.09$	5 0.08	0 0	$\begin{array}{c} 1\\ 0.01 \end{array}$	19 0.11	$10 \\ 0.10$	$\frac{1}{0.02}$	0.0030
4	Reoperation	Frequency Proportion	81 0.08	4 0.04	2 0.17	8 0.05	22 0.11	6 0.10	0 0	$\begin{array}{c} 1\\ 0.01 \end{array}$	23 0.13	11 0.11		0.0111
2	Abdominoperineal resection of rectal cancer	Sample size Frequency Proportion	384 67 0.17	37 4 0.11	5 0 0	57 10 0.18	109 27 0.25	27 8 0.30	0	23 3 0.13	83 11 0.13	28 3 0.11		0.1372
6	Perioperative blood loss (ml)	Sample size Median Min Max	964 300 0 4200	92 250 10 3500	12 500 100 1000	163 300 2 3000	204 200 10 2600	62 500 100 4000	13 500 100 1000	99 300 50 700	178 400 0 2500	96 300 20 4200	45 500 50 1800	<.0001
٢	Patients needing perioperative blood transfusions	Sample size Frequency Proportion	961 180 0.19	92 5 0.05	12 1 0.08	161 16 0.10	203 25 0.12	62 16 0.26	$\begin{array}{c} 13\\1\\0.08\end{array}$	99 22 0.22	177 70 0.40	97 17 0.18	45 7 0.16	<.0001
×	Perioperative blood loss for patients needing blood transfusion (ml)	Sample Size Median Min Max	180 400 0 4200	5 200 500 500	1 1000 1000 1000	16 550 50 3000	25 500 30 2000	16 500 150 2300	1 200 200	22 300 150 700	70 400 0 1700	17 300 50 4200	7 500 50 1000	0.0175
6	Tumors opened during mobilization	Sample size Frequency Proportion	961 50 0.05	90 6 0.07	12 0 0	163 14 0.09	204 9 0.04	62 7 0.11	$\begin{array}{c} 13\\1\\0.08\end{array}$	99 2 0.02	176 3 0.02	97 4 0.04	45 4 0.09	0.0499
10	T4-tumors not en-bloc resected (% of T4)	Sample size Frequency Proportion	121 13 0.11	0 0	0.	24 5 0.21	ь 0 0	с 0 0	3 1 0.33	$\begin{array}{c} 16\\ 0\\ 0 \end{array}$	25 1 0.04	20 4 0.20	10 2 0.20	0.1272
11	Cytotoxic irrigations of anorectal stump (% of rectal and rectosigmoid cancers with anterior resection)	Sample size Frequency Proportion	352 277 0.79	37 37 1.0	6 4 0.67	52 49 0.94	90 59 0.66	22 3 0.14	0	21 16 0.76	76 68 0.89	29 24 0.83	19 17 0.89	0.0005
12	Principles of mesorectal excision applied (% of rectal and rectosigmoid cancers) <sup>a</sup>	Sample size Frequency Proportion	445 416 0.93	41 41 1.0	6 6 1.0	69 63 0.91	119 115 0.97	33 28 0.85	0	27 24 0.90	96 87 0.91	33 32 0.97	21 20 0.95	0.1226



<ul> <li>13 Rectal cancer specimens with circumferential Sample size margin ≤1 mm<sup>a</sup> with circumferential Sample size area margin (mm)<sup>a</sup> Proportion</li> <li>14 Minimum histological distance from rectal Sample size cancer to circumferential resection Median margin (mm)<sup>a</sup> Min Min</li> <li>15 No-touch isolation</li> <li>15 No-touch isolation</li> <li>15 No-touch isolation</li> <li>16 latrogenically perforated mesocolon/mesorectum<sup>a</sup> Sample size to latrogenically perforated mesocolon/mesorectum<sup>a</sup> Sample size</li> </ul>	Total De	Dept1 Dept2	cidari	Dept4	CtdeU	Depto	Dept7	Dept8	Dept9	Dept10	P value
<ul> <li>Minimum histological distance from rectal cancer to circumferential resection margin (mm)<sup>a</sup></li> <li>No-touch isolation</li> <li>No-touch isolation</li> <li>technique:</li> <li>arterial ligature</li> <li>venous ligature</li> <li>closure of bowel lumen</li> <li>latrogenically perforated mesocolon/mesorectum<sup>a</sup></li> </ul>	e 301 29	27 4 5 0	47 6	86 2	22 1	0	19 3	69 10	17 2	10 0	0.1113
<ul> <li>Minimum histological distance from rectal cancer to circumferential resection margin (mm)<sup>a</sup></li> <li>No-touch isolation</li> <li>No-touch isolation</li> <li>technique:</li> <li>arterial ligature</li> <li>venous ligature</li> <li>closure of bowel lumen</li> <li>latrogenically perforated mesocolon/mesorectum<sup>a</sup></li> </ul>			0.13	0.02	0.05	Ι	0.16	0.14	0.12	0	
margin (mm) <sup>a</sup> No-touch isolation technique: - arterial ligature - venous ligature - closure of bowel lumen latrogenically perforated mesocolon/mesorectum <sup>a</sup>	206 8	3	36 5	27	14	0	16 11 5	69 10	6 "	C1 (*	0.0011
No-touch isolation technique: - arterial ligature - venous ligature - closure of bowel lumen latrogenically perforated mesocolon/mesorectum <sup>a</sup>	0 0		0	0.2	0.5	I	0	0	0.7	0 0	
No-touch isolation technique: - arterial ligature - venous ligature - closure of bowel lumen latrogenically perforated mesocolon/mesorectum <sup>a</sup>			30	60	50	Ι	40	45	28	9	
technique: - arterial ligature - venous ligature - closure of bowel lumen latrogenically perforated mesocolon/mesorectum <sup>a</sup>											
<ul> <li>arterial ligature</li> <li>venous ligature</li> <li>closure of bowel lumen</li> <li>latrogenically perforated mesocolon/mesorectum<sup>a</sup></li> </ul>	964 91	12	163	204	62	13	66	178	76	45	
<ul> <li>venous ligature</li> <li>closure of bowel lumen</li> <li>latrogenically perforated mesocolon/mesorectum<sup>a</sup></li> </ul>		50 0.50	0.36	0.78	0.71	0.38	0.86	0.76	0.81	0.47	<.0001
<ul> <li>closure of bowel lumen</li> <li>latrogenically perforated mesocolon/mesorectum<sup>a</sup></li> </ul>		0.68 0.50	0.36	0.80	0.73	0.38	0.86	0.76	0.81	0.40	<.0001
latrogenically perforated mesocolon/mesorectum <sup>a</sup>			0.34	0.51	0.58	0.92	0.75	0.52	0.13	0.49	<.0001
Fre	958	12	161	203	61	13	66	178	76	45	0.2691
	37 4	0	5	6	4	0	2	3	8	2	
Proportion	0.04 $0.04$	)4 0	0.03	0.04	0.07	0	0.02	0.02	0.08	0.04	

The sample sizes for a variable are given only if it differs from the overall sample sizes in No. 0. *P* values: chi-square tests for frequencies, Monte Carlo approximation for low frequencies; Kruskal-Wallis tests for measurements (summarized by median, min, max). Missing items excluded from analyses

Dept. surgical department

<sup>a</sup> Patients with transanal local excisions are excluded from this analysis

Table 7 (continued)

#### References

- Renzulli P, Lowy A, Maibach R, Egeli RA, Metzger U, Laffer UT (2006) The influence of the surgeon's and the hospital's caseload on survival and local recurrence after colorectal cancer surgery. Surgery 139(3):296–304
- Dorrance HR, Docherty GM, O'Dwyer PJ (2000) Effect of surgeon specialty interest on patient outcome after potentially curative colorectal cancer surgery. Dis *Colon rectum* 43(4):492–498
- Iversen LH, Harling H, Laurberg S, Wille-Jorgensen P, Danish Colorectal Cancer G (2007) Influence of caseload and surgical speciality on outcome following surgery for colorectal cancer: a review of evidence. Part 2: long-term outcome. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 9(1):38–46
- Phillips RK, Hittinger R, Blesovsky L, Fry JS, Fielding LP (1984) Local recurrence following 'curative' surgery for large bowel cancer: I. The overall picture. The British journal of surgery 71(1):12– 16
- Phillips RK, Hittinger R, Blesovsky L, Fry JS, Fielding LP (1984) Local recurrence following 'curative' surgery for large bowel cancer: II. The rectum and rectosigmoid. The British journal of surgery 71(1):17–20
- McArdle CS, Hole D (1991) Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ 302(6791):1501–1505
- Porter GA, Soskolne CL, Yakimets WW, Newman SC (1998) Surgeon-related factors and outcome in rectal cancer. Ann Surg 227(2):157–167
- Borowski DW, Kelly SB, Bradburn DM, Wilson RG, Gunn A, Ratcliffe AA, Northern Region Colorectal Cancer Audit G (2007) Impact of surgeon volume and specialization on short-term outcomes in colorectal cancer surgery. The British journal of surgery 94(7):880–889
- Iversen LH, Harling H, Laurberg S, Wille-Jorgensen P (2007) Influence of caseload and surgical speciality on outcome following surgery for colorectal cancer: a review of evidence. Part 1: shortterm outcome. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 9(1): 28–37
- Association of Coloproctology of Great Britain and Ireland (2007) Guidelines for the management of colorectal cancer. 3rd edn.
- Otchy D, Hyman NH, Simmang C, Anthony T, Buie WD, Cataldo P, Church J, Cohen J, Dentsman F, Ellis CN, Kilkenny JW III, Ko C, Moore R, Orsay C, Place R, Rafferty J, Rakinic J, Savoca P, Tjandra J, Whiteford M, Standards Practice Task F, American Society of C, Rectal S (2004) Practice parameters for colon cancer. Dis Colon rectum 47(8):1269–1284
- 12. Tjandra JJ, Kilkenny JW, Buie WD, Hyman N, Simmang C, Anthony T, Orsay C, Church J, Otchy D, Cohen J, Place R, Denstman F, Rakinic J, Moore R, Whiteford M, Standards Practice Task F, American Society of C, Rectal S (2005) Practice parameters for the management of rectal cancer (revised). Dis Colon rectum 48(3):411–423
- Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rodel C, Sauer R, Wieser M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I, Pox C (2008) Update S3-guideline "colorectal cancer" 2008. Zeitschrift fur Gastroenterologie 46(8):799–840
- 14. Maurer CA (2004) Colon cancer: resection standards. Techniques in coloproctology 8(Suppl 1):s29–s32
- Maurer CA, Renzulli P, Meyer JD, Buchler MW (1999) Rectal carcinoma. Optimizing therapy by partial or total mesorectum removal. Zentralblatt fur Chirurgie 124(5):428–435

- Sobin LHWC UICC International Union Against Cancer TNM classification of malignant tumours, 6th edn. Wiley, Lissabon, New York
- Turnbull RB Jr, Kyle K, Watson FR, Spratt J (1967) Cancer of the colon: the influence of the no-touch isolation technic on survival rates. Ann Surg 166(3):420–427
- Goldstein NS, Soman A, Sacksner J (1999) Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. The effects of surgical resection and formalin fixation on organ shrinkage. Am J Clin Pathol 111(3):349–351
- Kwok SP, Lau WY, Leung KL, Liew CT, Li AK (1996) Prospective analysis of the distal margin of clearance in anterior resection for rectal carcinoma. The British journal of surgery 83(7):969–972
- Weese JL, O'Grady MG, Ottery FD (1986) How long is the five centimeter margin? Surgery, gynecology & obstetrics 163(2):101– 103
- Neufeld D, Bugyev N, Grankin M, Gutman M, Klein E, Bernheim J, Shpitz B (2007) Specimen length as a perioperative surrogate marker for adequate lymphadenectomy in colon cancer: the surgeon's role. Int Surg 92(3):155–160
- Wang J, Kulaylat M, Rockette H, Hassett J, Rajput A, Dunn KB, Dayton M (2009) Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer? Ann Surg 249(4): 559–563
- Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG (2003) Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21(15):2912–2919
- Chen SL, Bilchik AJ (2006) More extensive nodal dissection improves survival for stages I to III of colon cancer: a populationbased study. Ann Surg 244(4):602–610
- 25. van Steenbergen LN, van Lijnschoten G, Rutten HJ, Lemmens VE, Coebergh JW (2010) Improving lymph node detection in colon cancer in community hospitals and their pathology department in southern Netherlands. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 36(2):135–140
- Wright FC, Law CH, Last L, Khalifa M, Arnaout A, Naseer Z, Klar N, Gallinger S, Smith AJ (2003) Lymph node retrieval and assessment in stage II colorectal cancer: a population-based study. Ann Surg Oncol 10(8):903–909
- 27. Rosenberg R, Friederichs J, Schuster T, Gertler R, Maak M, Becker K, Grebner A, Ulm K, Hofler H, Nekarda H, Siewert JR (2008) Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period. Ann Surg 248(6):968–978
- Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG (2005) Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23(34):8706–8712
- Peschaud F, Benoist S, Julie C, Beauchet A, Penna C, Rougier P, Nordlinger B (2008) The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer. Ann Surg 248(6):1067–1073
- Vaccaro CA, Im V, Rossi GL, Quintana GO, Benati ML, Perez de Arenaza D, Bonadeo FA (2009) Lymph node ratio as prognosis factor for colon cancer treated by colorectal surgeons. Dis Colon rectum 52(7):1244–1250
- 31. Hida J, Okuno K, Yasutomi M, Yoshifuji T, Uchida T, Tokoro T, Shiozaki H (2005) Optimal ligation level of the primary feeding artery and bowel resection margin in colon cancer surgery: the influence of the site of the primary feeding artery. Dis Colon rectum 48(12):2232–2237

- West NP, Morris EJ, Rotimi O, Cairns A, Finan PJ, Quirke P (2008) Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. The lancet oncology 9(9):857–865
- 33. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S (2009) Standardized surgery for colonic cancer: complete mesocolic excision and central ligation-technical notes and outcome. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 11(4):354–364
- Read TE, Mutch MG, Chang BW, McNevin MS, Fleshman JW, Birnbaum EH, Fry RD, Caushaj PF, Kodner IJ (2002) Locoregional recurrence and survival after curative resection of adenocarcinoma of the colon. J Am Coll Surg 195(1):33–40
- 35. Slanetz CA Jr, Grimson R (1997) Effect of high and intermediate ligation on survival and recurrence rates following curative resection of colorectal cancer. Dis Colon rectum 40(10):1205–1218
- Toyota S, Ohta H, Anazawa S (1995) Rationale for extent of lymph node dissection for right colon cancer. Dis Colon rectum 38(7): 705–711
- 37. Morikawa E, Yasutomi M, Shindou K, Matsuda T, Mori N, Hida J, Kubo R, Kitaoka M, Nakamura M, Fujimoto K et al (1994) Distribution of metastatic lymph nodes in colorectal cancer by the modified clearing method. Dis Colon rectum 37(3):219–223
- Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J (1993) Blood transfusions and prognosis in colorectal cancer. N Engl J Med 328(19):1372–1376

- Morris E, Quirke P, Thomas JD, Fairley L, Cottier B, Forman D (2008) Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene? Gut 57(12):1690–1697
- Zirngibl H, Husemann B, Hermanek P (1990) Intraoperative spillage of tumor cells in surgery for rectal cancer. Dis Colon rectum 33(7):610–614
- Slanetz CA Jr (1984) The effect of inadvertent intraoperative perforation on survival and recurrence in colorectal cancer. Dis Colon rectum 27(12):792–797
- 42. Eriksen MT, Wibe A, Syse A, Haffner J, Wiig JN, Norwegian Rectal Cancer G, Norwegian Gastrointestinal Cancer G (2004) Indvertent perforation during rectal cancer resection in Norway. The British journal of surgery 91(2):210–216
- 43. Maurer CA, Renzulli P, Kull C, Kaser SA, Mazzucchelli L, Ulrich A, Buchler MW (2011) The impact of the introduction of total mesorectal excision on local recurrence rate and survival in rectal cancer: long-term results. Ann Surg Oncol 18(7):1899–1906
- Maurer CA (2005) Urinary and sexual function after total mesorectal excision. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer 165: 196–204
- 45. Maurer CA, Z'Graggen K, Renzulli P, Schilling MK, Netzer P, Buchler MW (2001) Total mesorectal excision preserves male genital function compared with conventional rectal cancer surgery. The British journal of surgery 88(11):1501–1505